CMIC Holdings Co., Ltd.
Held a group measurement event for new corona neutralizing antibodies for high school soccer club members
– Visualization of corona resistance, clarification of vaccine usefulness –
CMIC Solutions Co., Ltd. (Headquarters: Minato-ku, Tokyo,
Representative Director and Co-CEO: Yoshiyuki Hano, Megumi Kasai, hereinafter: CMIC), a subsidiary of CMIC Holdings, announced the onset of the new coronavirus infection (hereinafter: COVID-19). Teikyo Nagaoka High School (Nagaoka City, Niigata Prefecture, Principal: Setsuo Asakawa, hereinafter: Teikyo Nagaoka High School) held its first group measurement event for “neutralizing antibodies” in the body, which are said to prevent illness and aggravation.
Group sports such as soccer are concerned about outbreaks of COVID-19, and managing the health of participating players has become a major issue.
Teikyo Nagaoka High School Men’s Soccer Club (hereinafter referred to as the same club) is famous as a soccer powerhouse, having won the national championship in the 2022 MIZUNO CHAMPIONSHIP U-16 Rookie League, in addition to being in the top 4 of the National High School Soccer Championship (2020, 2021). am. The club has also experienced mass infections of club members due to cluster outbreaks, and it was an urgent matter to protect the health and safety of club members. Therefore, CMIC targeted 106 high school students belonging to the same department, using the new coronavirus antibody test kit “SARS-CoV-2 saliva antibody test” (research reagent, hereinafter: this kit *) sold by CMIC , held the first “group measurement meeting” to collectively measure antibody levels. With this kit, saliva is collected and the amount of antibody can be visually checked by the gradation of the line score displayed on the kit. It is a simple kit that provides results in about 15 minutes. It has been approved by the U.S. Food and Drug Administration).
*This kit is a reagent for research.
After the group measurement session, the results of evaluation based on the presence or absence of COVID-19 infection, the number of COVID-19 vaccinations, and the antibody titer showed that there was no difference in the antibody titer between the presence or absence of COVID-19 infection, and the number of COVID-19 vaccinations. There was a tendency that the higher the number, the higher the antibody titer. It was suggested that it is effective to inoculate the vaccine regularly at the appropriate time for the prevention of aggravation. In general, it is said that a high antibody titer can prevent the onset and severity of the disease, and it is expected that regular measurement with this kit will also be useful as a means of preventing infection.
Based on the results of this test, the department is developing guidance based on the test results, such as recommending vaccinations for club members with low antibody titers and alerting them to lifestyle issues.
Taking advantage of this first-ever experience, CMIC plans to provide a new service called the “Antibody Testing Mass Measurement Service (tentative name)” to educational institutions, professional sports groups, and other groups where there are concerns about outbreaks. Although COVID-19 measures will continue, CMIC will continue to contribute to the prevention of the spread of COVID-19 by developing testing services and vaccination support in collaboration with local governments.
SARS-CoV-2 saliva antibody test sales page
Test kit mail-order site “Healthy Online Shop” (operated by CMIC Solutions) [Image 1
Color sample of test kit showing antibody titer
New coronavirus antibody test kit “SARS-CoV-2 saliva antibody test” (research reagent)
Group measurement meeting
Changes in antibody titers by number of vaccinations
■ About CMIC Group
CMIC (CMIC) started Japan’s first CRO (drug development support) business in 1992, and now provides comprehensive support services related to pharmaceuticals, from development to manufacturing, sales and marketing. Currently, CMIC Group is one of the largest CRO in Japan, and at the same time provides comprehensive services in drug development, SMO (clinical site support), drug manufacturing, regulatory affairs consulting, and sales and marketing solutions. We also actively support pharmaceutical, biotechnology, and medical device companies entering the Japanese market, conducting clinical trials in Asia, and supporting drug development and manufacturing in the United States and Japan. The CMIC Group has over 7,500 employees and 27 group companies worldwide.
Please see the website for details. https://www.cmicgroup.com
Details about this release: